[Asp371]-Tyrosinase (369-377), human

Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy[1][2].

Product Specifications

CAS Number

[168650-46-2]

UNSPSC

12352209

Target

Tyrosinase

Type

Peptides

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/asp371-tyrosinase-369-377-human.html

Purity

99.66

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

OC1=CC=C(C[C@@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](C(C)C)C(O)=O)=O)CCC(N)=O)=O)CO)=O)CCSC)=O)[C@@H](C)O)=O)=O)CC(O)=O)=O)CCSC)=O)N)C=C1

Molecular Formula

C42H66N10O16S2

Molecular Weight

1031.16

References & Citations

[1]Guillaume B, et al. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. J Immunol. 2012 Oct 1;189 (7) :3538-47.|[2]Mitchell MS, et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol. 2002 Feb 15;20 (4) :1075-86.